Xencor, Inc Payments To Acquire Equity Securities Fv Ni
Xencor, Inc (XNCR) reported Payments To Acquire Equity Securities Fv Ni of $842.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquitySecuritiesFvNi · last filed 2022-11-07
- 2021-09-30: Payments To Acquire Equity Securities Fv Ni 9 month $842.00K.
| Period end | Payments To Acquire Equity Securities Fv Ni 9 month |
|---|---|
| 2021-09-30 | $842.00K 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |